Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-38.9
Year-on-year change in net income attributable to owners of the parent (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2025年１月１日〜2025年３月31日ConsolidatedJapanese GAAPNet Sales4,423¥ millionYear on year +1.6%Progress 22.1%
Operating profit1,093¥ millionYear on year +3.8%Progress 21.9%
Ordinary income1,059¥ millionYear on year -6.5%Progress 20.8%
Net income attributable to owners of the parent476¥ millionYear on year -38.9%Progress 13.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share25.44円
Financial position at period-end
Total assets31,428¥ million
of which net assets 26,208 ¥ millionEquity ratio 83.4%vs. prior year-end +2.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueJapan ¥1,594 million (YoY -14.1%), Taiwan ¥860 million (YoY +8.2%), Zhuhai (China) ¥573 million (YoY +12.5%), Suzhou (China) ¥797 million (YoY +5.5%), Europe ¥400 million (YoY +54.1%), Thailand ¥197 million (YoY +11.8%)
Segment profitJapan ¥646 million (YoY -5.9%), Taiwan ¥94 million (YoY -28.5%), Zhuhai (China) ¥76 million (YoY -29.8%), Suzhou (China) ¥78 million (YoY -49.1%), Europe ¥48 million (YoY +403.3%), Thailand ¥27 million (YoY +1.7%)
Regional sales¥1,594 million (YoY -14.1%), ¥860 million (YoY +8.2%), ¥573 million (YoY +12.5%), ¥797 million (YoY +5.5%), ¥400 million (YoY +54.1%), ¥197 million (YoY +11.8%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥20,000 million (YoY +9.7%)
Operating profit¥5,000 million (YoY +9.6%)
Ordinary income¥5,100 million (YoY +8.9%)
Net income¥3,600 million (YoY +57.1%)
Revision to Earnings ForecastNo
Annual Dividend Forecast¥45 → ¥55（+22.2%）
Factors Behind Changes in Business Performance
薬品は生成AI関連など先端パッケージ基板向けの需要が堅調に推移した一方、機械売上の減少や主要為替相場の影響を受け、売上高は微増となった。販売費及び一般管理費は主に人件費等が増加し、海外子会社からの配当金増加に伴い法人税等が増加した。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew No / Excluded No / Company name Not disclosed
Breakdown of extraordinary income (loss)Extraordinary income None recorded for the current period / Extraordinary loss Loss on Disposal of Fixed Assets ¥2,226 thousand
Depreciation and amortization¥195,144 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End20,071,093株
Treasury Shares at Period-End1,346,241株
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年１月１日〜2025年３月31日 |
| Net Sales | ¥4,423 million (YoY +1.6%) |
| Operating profit | ¥1,093 million (YoY +3.8%) |
| Ordinary income | ¥1,059 million (YoY -6.5%) |
| Profit attributable to owners of the parent | ¥476 million (YoY -38.9%) |
| Net income per share | 25.44円 |
| Equity ratio | End of the current fiscal period 83.4 / End of previous period 81.4 |
| Total assets | ¥31,428 million |
| Net assets | ¥26,208 million |
| Full-year earnings forecast | Net Sales ¥20,000 million (YoY +9.7%) / Operating profit ¥5,000 million (YoY +9.6%) / Ordinary income ¥5,100 million (YoY +8.9%) / Net income ¥3,600 million (YoY +57.1%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥45 → ¥55（+22.2%） |
| Segment revenue | Japan ¥1,594 million (YoY -14.1%), Taiwan ¥860 million (YoY +8.2%), Zhuhai (China) ¥573 million (YoY +12.5%), Suzhou (China) ¥797 million (YoY +5.5%), Europe ¥400 million (YoY +54.1%), Thailand ¥197 million (YoY +11.8%) |
| Segment profit | Japan ¥646 million (YoY -5.9%), Taiwan ¥94 million (YoY -28.5%), Zhuhai (China) ¥76 million (YoY -29.8%), Suzhou (China) ¥78 million (YoY -49.1%), Europe ¥48 million (YoY +403.3%), Thailand ¥27 million (YoY +1.7%) |
| Regional sales | ¥1,594 million (YoY -14.1%), ¥860 million (YoY +8.2%), ¥573 million (YoY +12.5%), ¥797 million (YoY +5.5%), ¥400 million (YoY +54.1%), ¥197 million (YoY +11.8%) |
| Depreciation and amortization | ¥195,144 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income None recorded for the current period / Extraordinary loss Loss on Disposal of Fixed Assets ¥2,226 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New No / Excluded No / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 20,071,093株 |
| Treasury Shares at Period-End | 1,346,241株 |
| Factors Behind Changes in Business Performance | 薬品は生成AI関連など先端パッケージ基板向けの需要が堅調に推移した一方、機械売上の減少や主要為替相場の影響を受け、売上高は微増となった。販売費及び一般管理費は主に人件費等が増加し、海外子会社からの配当金増加に伴い法人税等が増加した。 |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.薬品は生成AI関連など先端パッケージ基板向けの需要が堅調だったが、機械売上の減少や主要為替相場の影響により売上高は微増となった。販売費及び一般管理費は主に人件費等が増加し、海外子会社からの配当金増加に伴って法人税等も増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.